MedTrace Logo

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

NCT04706286 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-01-12

No results posted yet for this study

Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

CKD-501, D759, D150

CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition

DRUG

CKD-393 0.5/100/1000 mg

CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Choon Ok Kim, M.D., Ph.D. · Severance hospital of the Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2021-03-29
Completion
2021-04-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706286 on ClinicalTrials.gov